"We're in the process now of attaining insurance coverage for lenacapavir," Daniel O'Day, chairman and CEO of Gilead Sciences, said at a September press conference. "It's going as planned. We expect within six months of launch to have around 75 percent of insurers covering lenacapavir and about 90 percent in 12 months. And that plan is very actively underway right now for Americans."